Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-12-25
2007-12-25
Richter, Johann (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S263340, C514S456000, C514S689000, C424S653000, C424S709000, C424S711000
Reexamination Certificate
active
10927742
ABSTRACT:
The subject invention pertains to materials and methods for the prevention and treatment of gastrointestinal diseases, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Therapeutic compositions of the invention include compositions that can neutralize hydrogen peroxide, such as reducing agents and oxidizing agents. In one embodiment, a therapeutic composition of the invention comprises a reducing agent such as sodium thiosulfate. Therapeutic compositions of the invention can optionally include compounds with antibacterial activity, compositions that inhibit bacterial adherence to cells and tissue, compositions that inhibits epithelial lipid peroxidation, compositions that add viscosity to a solution, compositions that inhibit most cells, and/or compositions that help to seal or repair tight junctions between cells of the colonic epithelium of the gastrointestinal tract. Methods of the invention include administration of compounds or compositions of the invention. In one embodiment, compounds or compositions of the invention are rectally instilled in a patient.
REFERENCES:
patent: 5563131 (1996-10-01), Berliner et al.
patent: 5817630 (1998-10-01), Hofmann et al.
Babior BM et al. Journal of Biological Chemistry 1981, 265(5), 2321-2323.
STN accession No. 94:19076 Kondracki Dissertation Abstracts International 1993, 54(12B) p. 6208.
Edwin van den Worm Investigation on apocynin a potent NADPH oxidase inhibitor publication date: May 2001. title page and p. 75.
Pfaff et al. Chromotographia 1999, 48(11/12), 666-670.
Doussiere et al. Eur. J. Biochem. 1992, 208, 61-71.
Abraham, N. et al. “Is smoking an indirect risk factor for the development of ulcerative colitis? An age- and sex-matched case-control study”Journal of Gastroenterology and Hepatology, 2003, pp. 139-146, vol. 18.
Allison, M. C. et al. “Prevalence of proximal faecal stasis in active ulcerative colitis”Gut, 1991, pp. 179-182, vol. 32.
Aw, T. Y. “Molecular and cellular responses to oxidative stress and changes in oxidation-reduction imbalance in the intestine”Am. J. Clin. Nutr., 1999, pp. 557-565, vol. 70.
Bagchi, D. et al. “Stress, Diet and Alcohol-induced Oxidative Gastrointestinal Mucosal Injury in Rats and Protection by Bismuth Subsalicylate”J. Appl. Toxicol, 1998, pp. 3-13, vol. 18, No. 1.
Basit, A. et al. “Perspectives on Colonic Drug Delivery”Pharmatech, 2003, pp. 185-190.
Batist, G. et al. “Interindividual variation in phase II detoxification enzymes in normal human colon mucosa”Biochemical Pharmacology, 1988, pp. 4241-4243, vol. 37, No. 21.
Beaugerie, L. et al. “Impact of Cessation of Smoking on the Course of Ulcerative Colitis”The American Journal of Gastroenterology, 2001, pp. 2113-2116, vol. 96, No. 7.
Benson, K. W. et al. “Fecal Impaction”Am. J. Sc., 1939, pp. 541-545, vol. 198.
Bertz, R. J. et al. “Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions” Mar. 1997, pp. 210-258, vol. 32, No. 3.
Beutler, E. et al. “Ethnic Variation in Red Cell Glutathione Peroxidase Activity”Blood, Jul. 1975, pp. 103-110, vol. 46, No. 1.
Black, D. A. et al. “Transit Time in Ulcerative Proctitis”Scand. J. Gastroenterol, 1987, pp. 872-876, vol. 22.
Blau, S. et al. “Differences in the reducing power along the rat GI tract: Lower antioxidant capacity of the colon”Molecular and Cellular Biochemistry, 1999, pp. 185-191, vol. 194.
Boveris, A. et al. “The Mitochondrial Generation of Hydrogen Peroxide”Biochem. J., 1973, pp. 707-716, vol. 134.
Boveris, A. et al. “The Cellular Production of Hydrogen Peroxide”Biochem. J., 1972, pp. 617-630, vol. 128.
Boveris, A. et al. “Mitochondrial Production of Hydrogen Peroxide Regulation by Nitric Oxide and the Role of Ubisemiquinone”Life, 2000, pp. 245-250, vol. 50.
Brunner, L. S. “Perioperative Management of the Surgical Patient” InTextbook of Medical Surgical Nursing, 4th edition, 1980, p. 358, Lippincott, Philadelphia.
Cadenas, E. et al. “Mitochondrial Free Radical Generation, Oxidative Stress, and Aging”Free Radical Biology&Medicine, 2000, pp. 222-230, vol. 29, Nos. 3-4.
Caprari, P. et al. “6-Phosphogluconate dehydrogenase deficiency in an Italian family”Ann. Hematol., 2001, pp. 41-44, vol. 80.
Carpenter, H. A. et al. “The Importance of Clinicopathological Correlation in the Diagnosis of Inflammatory Conditions of the Colon: Histological Patterns With Clinical Implications”The American Journal of Gastroenterology, 2000, pp. 878-896, vol. 95, No. 4.
Chance, B. et al. “Hydroperoxide Metabolism in Mammalian Organs”Physiological Reviews, Jul. 1979, pp. 527-605, vol. 59, No. 3.
Chen, N. et al. “Physiologic concentrations of homocysteine inhibit the human plasma GSH peroxidase that reduces organic hydroperoxides”J. Lab. Clin. Med., 2000, pp. 58-65, vol. 136, No. 1.
Chen, S. et al. “Hydroxyl-radical production in physiological reactions”Eur. J. Biochem., 1999, pp. 726-735, vol. 260.
Cho, J. H. et al. “Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, 4q: Evidence for epistasis between 1p andIBD1” Proc. Natl. Acad. Sci. USA, Jun. 1998, pp. 7502-7507, vol. 95.
Cho, J. H. et al. “Linkage and linkage disequillibrium in chromosome band 1p36 in American Chaldeans with inflammatory bowel disease”Human Molecular Genetics, 2000, pp. 1425-1432, vol. 9, No. 9.
Ciftci, M. et al. “Effects of Some Drugs on Rat Erythrocyte 6-Phosphogluconate Dehydrogenase: An In Vitro and In Vivo Study”Polish Journal of Pharmacology, 2002, pp. 275-280, vol. 54.
Dalekos G. N. et al. “Zinc, copper and immunological markers in the circulation of well nourished patients with ulcerative colitis”Eur. J. Gastroenterol Hepatol., Apr. 1998, pp. 331-337, vol. 10, No. 4, abstract only.
Davidson, R. G. “Electrophoretic variants of human 6-phosphogluconate dehydrogenase: population and family studies and description of a new variant”Ann. Hum. Genet., 1967, pp. 355-361, vol. 30.
Davies, K. J. A. “Oxidative Stress, Antioxidant Defenses, and Damage Removal, Repair, and Replacement Systems”Life, 2000, pp. 279-289, vol. 50.
Dern, R. J. et al. “Hereditary variation of erythrocytic 6-phosphogluconate dehydrogenase”J. Lab.&Clin. Med., Feb. 1966, pp. 255-264, vol. 67, No. 2.
Drossman, D. et al. “Rome II: the functional gastrointestinal disorders : diagnosis, pathophysiology, and treatment : a multinational consensus” inThe Functional Gastrointestinal Disorders, 2000, eds. Douglas A. Dross, Enrico Corazziari, Library of Congress Catloging-in-Publication Data.
Drossman, D. A. et al. “U.S. Householder Survey of Functional Gastrointestinal Disorders”Digestive Diseases and Sciences, Sep. 1993, pp. 1569-1580, vol. 38, No. 9.
Duncan, G. G. “Folic Acid (Folacin)” InDiseases of Metabolism—Detailed Methods of Diagnosis and Treatment, 5th edition, 1964, pp. 614-618, W. B. Saunders Company, Philadelphia and London.
Eaton, J. W. et al. “Acatalasemia” InThe Metabolic&Molecular Bases of Inherited Disease, 7th edition, Chapter 74, eds., Scriver et al., 1995, pp. 2371-2379, McGraw-Hill Medical Publishing Division.
Eaton, J. W. et al. “Molecular Bases of Cellular Iron Toxicity”Free Radical Biology&Medicine, 2002, pp. 833-840, vol. 32, No. 2.
Eberhardt, M. K. et al., InReactive Oxygen Metabolites—Chemistry and Medical Consequences, 2001, pp. 23, 51, 63, 64, 81, 118, 125, and 262, CRC Press.
Elsborg, L. et al. “Folate Deficiency in Chronic Inflammatory Bowel Diseases”Scand. J. Gastroent., 1979, pp. 1019-1023, vol. 14.
Everhart, J. E. et al. “A Longitudinal Survey of Self-Reported Bowel Habits in the United States”Digestiv
Arnold Ernst V
Richter Johann
Saliwanchik Lloyd & Saliwanchik
LandOfFree
Materials and methods for treatment of gastrointestinal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Materials and methods for treatment of gastrointestinal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Materials and methods for treatment of gastrointestinal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3829217